News

Our heartfelt sympathy goes out to the people who have been affected by the Coronavirus Disease (COVID-19). With the continuing spread of COVID-19, we are, as part of our mission as a pharmaceutical company, taking various actions and measures to contribute to securing the safety of patients and alleviating strain on healthcare resources. The following are our activities and status to date in...

- Study meets primary endpoint demonstrating non-inferiority of roxadustat to darbepoetin in correction and maintenance of hemoglobin levels - Findings presented today in oral session at the European Renal Association-European Dialysis and Transplant Association Virtual Congress 2020 TOKYO, June 8, 2020 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today...

- Fitness Services are planned for launch in 2020 - TOKYO, June 5, 2020 - Astellas Pharma Inc. (Tokyo, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) developed science-based exercise programs in cooperation with the City of Yokohama, Kanagawa Prefecture (Kanagawa, Mayor: Fumiko Hayashi, "City of Yokohama”) and Yokohama City University (Kanagawa, Chairperson of the Board of Trustees and CEO...

Data simultaneously published in the New England Journal of Medicine and presented during the virtual scientific program of the 2020 ASCO Annual Meeting NEW YORK and TOKYO, May 29, 2020 – Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) have announced final results from the overall survival (OS) analysis of the Phase 3 PROSPER trial...

XTANDI is now MHLW-approved for both metastatic hormone-sensitive prostate cancer and castration-resistant prostate cancer in Japan TOKYO, May 29, 2020 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced that the Japan Ministry of Health, Labour and Welfare (MHLW) has approved XTANDI® (enzalutamide), an oral androgen receptor signaling inhibitor...